JPWO2020014139A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020014139A5 JPWO2020014139A5 JP2020569041A JP2020569041A JPWO2020014139A5 JP WO2020014139 A5 JPWO2020014139 A5 JP WO2020014139A5 JP 2020569041 A JP2020569041 A JP 2020569041A JP 2020569041 A JP2020569041 A JP 2020569041A JP WO2020014139 A5 JPWO2020014139 A5 JP WO2020014139A5
- Authority
- JP
- Japan
- Prior art keywords
- once
- methyl
- combination according
- administered
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695630P | 2018-07-09 | 2018-07-09 | |
| US62/695,630 | 2018-07-09 | ||
| PCT/US2019/040838 WO2020014139A1 (en) | 2018-07-09 | 2019-07-08 | Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021532067A JP2021532067A (ja) | 2021-11-25 |
| JP2021532067A5 JP2021532067A5 (https=) | 2022-07-12 |
| JPWO2020014139A5 true JPWO2020014139A5 (https=) | 2022-07-12 |
| JP7352582B2 JP7352582B2 (ja) | 2023-09-28 |
Family
ID=69142959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569041A Active JP7352582B2 (ja) | 2018-07-09 | 2019-07-08 | Ｓｕｍｏ活性化酵素阻害剤及び抗ｃｄ２０抗体の投与 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12097199B2 (https=) |
| EP (1) | EP3820475A4 (https=) |
| JP (1) | JP7352582B2 (https=) |
| KR (1) | KR20210031679A (https=) |
| CN (1) | CN112384219A (https=) |
| AU (1) | AU2019300852A1 (https=) |
| BR (1) | BR112021000169A2 (https=) |
| CA (1) | CA3105947A1 (https=) |
| MX (1) | MX2021000349A (https=) |
| TW (1) | TW202019422A (https=) |
| WO (1) | WO2020014139A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020176643A1 (en) * | 2019-02-26 | 2020-09-03 | Millennium Pharmaceuticals, Inc. | Compounds useful as adjuvants |
| WO2021203001A1 (en) * | 2020-04-03 | 2021-10-07 | Millennium Pharmaceuticals, Inc. | Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme |
| BR112022023137A2 (pt) * | 2020-05-15 | 2023-02-07 | Takeda Pharmaceuticals Co | Administração de inibidor de enzima de ativação de sumo e anticorpos anti-cd38 |
| WO2025029578A1 (en) * | 2023-08-03 | 2025-02-06 | Duke University | Sumoylation as a therapeutic target in inflammatory bowel diseases and infections disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| CA2340091C (en) | 1998-08-11 | 2013-02-05 | Idec Pharmaceuticals Corporation | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| CN101928344B (zh) * | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EA024006B1 (ru) * | 2006-02-02 | 2016-08-31 | Миллениум Фармасьютикалз, Инк. | Ингибиторы е1 активирующих ферментов |
| WO2010043582A1 (en) * | 2008-10-17 | 2010-04-22 | Santaris Pharma A/S | Method for the treatment of cancer |
| WO2010044892A1 (en) | 2008-10-17 | 2010-04-22 | President And Fellows Of Harvard College | Diagnostic method based on large scale identification of post-translational modification of proteins |
| US9434765B2 (en) | 2011-05-24 | 2016-09-06 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | High affinity SUMO traps |
| JP6378759B2 (ja) | 2013-07-02 | 2018-08-22 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物 |
| SG11201610476VA (en) * | 2014-07-01 | 2017-01-27 | Millennium Pharm Inc | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| JP7126941B2 (ja) | 2015-12-22 | 2022-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ |
| KR20210131316A (ko) * | 2019-02-27 | 2021-11-02 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Sumo-활성화 효소 저해제 및 관문 저해제의 투여 |
-
2019
- 2019-07-08 JP JP2020569041A patent/JP7352582B2/ja active Active
- 2019-07-08 US US17/258,845 patent/US12097199B2/en active Active
- 2019-07-08 KR KR1020217000097A patent/KR20210031679A/ko not_active Withdrawn
- 2019-07-08 CN CN201980044629.7A patent/CN112384219A/zh active Pending
- 2019-07-08 AU AU2019300852A patent/AU2019300852A1/en not_active Abandoned
- 2019-07-08 CA CA3105947A patent/CA3105947A1/en active Pending
- 2019-07-08 MX MX2021000349A patent/MX2021000349A/es unknown
- 2019-07-08 WO PCT/US2019/040838 patent/WO2020014139A1/en not_active Ceased
- 2019-07-08 EP EP19835170.2A patent/EP3820475A4/en not_active Withdrawn
- 2019-07-08 BR BR112021000169-7A patent/BR112021000169A2/pt not_active IP Right Cessation
- 2019-07-09 TW TW108124148A patent/TW202019422A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532067A5 (https=) | ||
| Grillo-Lopez et al. | Rituximab the first monoclonal antibody approved for the treatment of lymphoma | |
| Dotan et al. | Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma | |
| Robak et al. | New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies | |
| Cheson | Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies | |
| Feuring-Buske et al. | IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group | |
| US12097199B2 (en) | Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies | |
| US11701428B2 (en) | Therapeutic combinations comprising anti-CD123 immunoconjugates | |
| TW202340259A (zh) | 抗cd19藥劑之劑量方案及其用途 | |
| JPWO2020014139A5 (https=) | ||
| Nabhan et al. | Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia | |
| Martin et al. | Phase I to III Trials of Anti–B Cell Therapy in Non–Hodgkin's Lymphoma | |
| KR20210131316A (ko) | Sumo-활성화 효소 저해제 및 관문 저해제의 투여 | |
| RU2021102613A (ru) | Введение ингибитора sumo-активирующего фермента и анти-cd20 антител | |
| EP0565642A1 (en) | Method of preventing inflammatory damage | |
| CA3178655A1 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies | |
| Witkowska et al. | Development of Anti-CD20 antigen-targeting therapies for B-cell lymphoproliferative malignancies-the state of the art | |
| Wenger et al. | Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? | |
| Grimsley et al. | Monoclonal antibodies in cancer | |
| JP2023540618A (ja) | 癌の併用療法 | |
| Tsimberidou | Mechanism of Action | |
| JPWO2022098628A5 (https=) | ||
| Kolyovska et al. | New perspectives in multiple sclerosis treatment | |
| O'Brien | ASH 2009 meeting report—Top 10 clinically oriented abstracts in chronic lymphocytic leukemia | |
| Herold et al. | Acute Toxicity of Mitoxantrone, Chlorambucil and Prednisolone (MCP) versus MCP plus Rituximab in Low-Grade Non-Hodgkin’s Lymphoma–Interim Results of a Phase III Trial |